| Market Cap | 123.11B | P/E | 15.65 | EPS this Y | 11.90% | Ern Qtrly Grth | -45.90% |
| Income | 3.13B | Forward P/E | 13.67 | EPS next Y | 5.70% | 50D Avg Chg | 2.00% |
| Sales | 30.93B | PEG | 2.93 | EPS past 5Y | 4.12% | 200D Avg Chg | -7.00% |
| Dividend | 3.00% | Price/Book | 23.02 | EPS next 5Y | 5.60% | 52W High Chg | -22.00% |
| Recommedations | 2.40 | Quick Ratio | 0.76 | Shares Outstanding | 537.33M | 52W Low Chg | 9.00% |
| Insider Own | 0.25% | ROA | 4.48% | Shares Float | 535.85M | Beta | 0.61 |
| Inst Own | 80.93% | ROE | 49.27% | Shares Shorted/Prior | 9M/9.24M | Price | 230.41 |
| Gross Margin | 63.41% | Profit Margin | 10.12% | Avg. Volume | 2,558,209 | Target Price | 332.30 |
| Oper. Margin | 22.91% | Earnings Date | Oct 30 | Volume | 2,550,177 | Change | -0.74% |
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout. It also markets other products, including Neulasta, MVASI, AMJEVITA/AMGEVITA, TEZSPIRE, Parsabiv, Aimovig, LUMAKRAS/LUMYKRAS, EPOGEN, KANJINTI, TAVNEOS, RAVICTI, UPLIZNA and PROCYSBI. The company serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. The company has collaboration agreements with AstraZeneca plc for the development and commercialization of TEZSPIRE; Novartis Pharma AG to develop and commercialize Aimovig; UCB for the development and commercialization of EVENITY; Kyowa Kirin Co., Ltd. for rocatinlimab development and commercialization; and BeiGene, Ltd. for oncology products expansion and development. Amgen Inc. was incorporated in 1980 and is headquartered in Thousand Oaks, California.
| Cantor Fitzgerald | Overweight | Sep 27, 24 |
| RBC Capital | Outperform | Sep 26, 24 |
| Baird | Underperform | Sep 25, 24 |
| TD Cowen | Buy | Aug 7, 24 |
| Oppenheimer | Outperform | Aug 7, 24 |
| Deutsche Bank | Hold | Aug 7, 24 |
| B of A Securities | Neutral | Aug 7, 24 |
| RBC Capital | Outperform | Aug 7, 24 |
| Wells Fargo | Equal-Weight | Aug 7, 24 |
| Insider Trades | Relationship | Date | Transactions | Cost($) | #Shares | Value($) | #Share Own | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| Grygiel Nancy A. | SVP & CCO SVP & CCO | Dec 04 | Sell | 273.0323 | 2,096 | 572,276 | 10,874 | 12/04/23 |
| Graham Jonathan P | EVP, Gen. Counsel &.. EVP, Gen. Counsel & Secy. | Nov 08 | Sell | 272.8136 | 10,000 | 2,728,136 | 28,078 | 11/13/23 |
| Gordon Murdo | EVP, Global Commerci.. EVP, Global Commercial Ops | Aug 10 | Sell | 262.43 | 9,558 | 2,508,306 | 44,308 | 08/11/23 |
| Khosla Rachna | SVP, Business Develo.. SVP, Business Development | Nov 09 | Sell | 292.90 | 387 | 113,352 | 6,630 | 11/10/22 |
| Grygiel Nancy A. | SVP & CCO SVP & CCO | Nov 05 | Sell | 293.54 | 545 | 159,979 | 13,009 | 11/08/22 |
| Williams R Sanders | Director Director | Aug 22 | Sell | 249.96 | 200 | 49,992 | 5,301 | 08/22/22 |
| ECKERT ROBERT | Director Director | Aug 18 | Sell | 248.9966 | 6,600 | 1,643,378 | 21,184 | 08/19/22 |
| ECKERT ROBERT | Director Director | Aug 10 | Option | 85.59 | 20,000 | 1,711,800 | 34,575 | 08/12/22 |
| Williams R Sanders | Director Director | May 23 | Sell | 250.00 | 600 | 150,000 | 5,501 | 05/23/22 |
| Graham Jonathan P | EVP, Gen. Counsel &.. EVP, Gen. Counsel & Secy. | May 10 | Sell | 241.8114 | 13,500 | 3,264,454 | 37,333 | 05/10/22 |
| SUGAR RONALD D | Director Director | May 12 | Option | 71.64 | 1,000 | 71,640 | 16,927 | 05/12/21 |
| SUGAR RONALD D | Director Director | May 12 | Sell | 250.59 | 1,000 | 250,590 | 15,927 | 05/12/21 |
| Grygiel Nancy A. | SVP & CCO SVP & CCO | May 12 | Option | 162.6 | 2,500 | 406,500 | 14,961 | 05/12/21 |
| Grygiel Nancy A. | SVP & CCO SVP & CCO | May 12 | Sell | 252.51 | 2,500 | 631,275 | 12,461 | 05/12/21 |
| SUGAR RONALD D | Director Director | Apr 15 | Option | 71.64 | 1,000 | 71,640 | 16,927 | 04/15/21 |
| SUGAR RONALD D | Director Director | Apr 15 | Sell | 249.98 | 1,000 | 249,980 | 15,927 | 04/15/21 |
| SUGAR RONALD D | Director Director | Mar 10 | Option | 71.64 | 1,000 | 71,640 | 16,805 | 03/10/21 |
| SUGAR RONALD D | Director Director | Mar 10 | Sell | 231.53 | 1,000 | 231,530 | 15,805 | 03/10/21 |
| Bradway Robert A | Chairman, CEO and Pr.. Chairman, CEO and President | Feb 22 | Option | 54.69 | 73,500 | 4,019,715 | 618,380 | 02/22/21 |
| REESE DAVID M | EVP, Research and De.. EVP, Research and Development | Feb 16 | Option | 54.69 | 2,300 | 125,787 | 42,059 | 02/16/21 |
| SUGAR RONALD D | Director Director | Feb 10 | Option | 71.64 | 1,000 | 71,640 | 16,805 | 02/10/21 |
| SUGAR RONALD D | Director Director | Feb 10 | Sell | 238.4 | 1,000 | 238,400 | 15,805 | 02/10/21 |
| SUGAR RONALD D | Director Director | Jan 14 | Option | 71.64 | 1,000 | 71,640 | 16,805 | 01/14/21 |
| SUGAR RONALD D | Director Director | Jan 14 | Sell | 235.99 | 1,000 | 235,990 | 15,805 | 01/14/21 |